Amyloid proteins and peptides form aggregates which lead to amyloid diseases. For example, Alzheimer's diseaserelated amyloid b (Ab) forms oligomers, protoˆbrils, and amyloidˆbrils, which exhibit neurotoxicity. Controlling the aggregation and toxicity of Ab would be a therapeutic strategy for the treatment of Alzheimer's disease. Recently, we have investigated an artiˆcial oxygenative modiˆcation (chemical introduction of oxygen atoms) of amyloid proteins using a photocatalyst, which attenuated the aggregation potency and toxicity of these proteins. The oxygenation of Ab1 42 was e‹ciently induced using a ribo‰avin catalyst (1). The oxygenated Ab was less aggregative and cytotoxic than native Ab. The oxygenated Ab also showed inhibitory activity against aggregation and the onset of toxicity of native Ab. Flavin catalyst 2, bearing an Ab-binding peptide, allowed the selective oxygenation of Ab even in the presence of living cells, due to its Ab-a‹nity. Furthermore,``On/OŠ'' switchable photooxygenation catalysts 3 and 4, which can sense a higher-order amyloid structure (i.e., cross-b-sheet structure), were developed based on the amyloid ‰uorescence probe thio‰avin-T. The photo-excited catalysts generated singlet oxygens to induce oxygenation when binding to the amyloid structure (``On''). In contrast, the free catalysts, without binding to the amyloid structure, produced no singlet oxygen, even if photo-excited (``OŠ''). This``On/OŠ'' switchable function enabled highly Ab-selective oxygenation. Catalyst 3 was successfully used for the selective oxygenation of other amyloid proteins and peptides. Theseˆndings suggest that amyloid-selective oxygenation could provide a versatile system in developing eŠective new treatments for amyloid diseases. 
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